Faculty of Medicine

Z7_NQ5E12C0LOF160QDKRNCOGGJA1

Research group

Spanish

Pharmacology and Toxicology Research Group INFARTO

Academic Unit: Faculty of Medicine

Colombian Ministry of Science

A

Call

894 GrupLAC

OECD

Area

Medical and health sciences

Subarea

Health sciences

Download Fact Sheet

Strategic Focus

We aim to become the leading group in Latin America within the next five years in clinical and pharmacological research in topics such as economic evaluation of medicines and health technologies, respiratory diseases, and clinical toxicology.

Research Lines and/or Areas

Pharmacoeconomics.
Pharmacoepidemiology.
Pharmacogenetics
Respiratory Diseases.

Sustainable Development Goals (SDGs)

Group Coordinator

Jefferson Antonio Buendía Rodríguez, MD, M.Sc., Ph.D.

Ph.D. in Pharmacy and Biochemistry.

Universidad de Buenos Aires, Argentina.

Coordinator's Email

jefferson.buendia@udea.edu.co

Scientific Cooperation

Collaborative Relationships

Academic networks with Infant Foundation, Vanderbilt University.
Respira: Respiratory Diseases in Children Study Group Universidad Nacional de Colombia.
Central Military Hospital, Pediatric Pneumology Section.

Highlighted Projects

Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage.
Costs of Respiratory Syncytial Virus Hospitalizations in Colombia.
Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Cost-effectiveness of diagnostic strategies of severe bacterial infection in infants with fever without a source.
Development of an antifibrotic scaffold platform mediator of tissue regeneration as therapeutic approach for the endomyocardial fibrosis treatment in the Department of Antioquia. General Royalties System.
Colombian Ministry of Science.

Key Research Findings

Costs of Respiratory Syncytial Virus Hospitalizations in Colombia, DOI: 10.1007/s41669-020-00218-7
Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis. DOI: 10.5546/aap.2019.eng.e466
Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage. DOI: 10.1186/s13104-019-4598-0